Guillain-Barré syndrome triggered by influenza vaccination in a recipient of liver transplant on FK506.
Guillain-Barré syndrome (GBS) has been rarely reported after liver transplantation and generally has good outcome. We report a liver transplant patient on FK506 (tacrolimus) who developed GBS 6 months after liver transplantation. There was no evidence of liver rejection or active infection. Despite treatment with intravenous immunoglobulin, the patient expired. GBS occurred despite downregulation of T cells by FK506, suggesting that humoral dysfunction might be the predominant mechanism of GBS in this report.
Moon
Joon-Shik
JS
Department of Neurology, UMDNJ-New Jersey Medical School, Newark, NJ 07101, USA.
Souayah
Nizar
N
D017809:Fatal Outcome; D020275:Guillain-Barre Syndrome / Q000209:etiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007252:Influenza Vaccines / Q000009:adverse effects*; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D016559:Tacrolimus / Q000627:therapeutic use*; D014611:Vaccination
D007166:Immunosuppressive Agents; D007252:Influenza Vaccines; D016559:Tacrolimus